Safety and Efficacy Study of 68Ga-Dotatoc Positron Emission Tomography for Diagnosis for Staging, Restaging and Assessment of Response to Treatment in Somatostatin Receptor-Positive Neuroendocrine Tumors

Trial Profile

Safety and Efficacy Study of 68Ga-Dotatoc Positron Emission Tomography for Diagnosis for Staging, Restaging and Assessment of Response to Treatment in Somatostatin Receptor-Positive Neuroendocrine Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 May 2017

At a glance

  • Drugs Gallium 68-DOTATOC (Primary)
  • Indications Carcinoid tumour; Neuroendocrine tumours
  • Focus Diagnostic use
  • Most Recent Events

    • 01 May 2017 Status changed from active, no longer recruiting to discontinued.
    • 23 Mar 2017 Planned End Date changed from 28 Feb 2017 to 1 Mar 2018.
    • 23 Mar 2017 Planned primary completion date changed from 28 Feb 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top